Adma biologics, inc.ADMA.US Overview
ADMA Overall Performance
ADMA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ADMA Key Information
ADMA Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ADMA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ADMA Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Price of ADMA
ADMA FAQ
When is ADMA's latest earnings report released?
The most recent financial report for Adma biologics, inc. (ADMA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADMA's short-term business performance and financial health. For the latest updates on ADMA's earnings releases, visit this page regularly.
Where does ADMA fall in the P/E River chart?
According to historical valuation range analysis, Adma biologics, inc. (ADMA)'s current price-to-earnings (P/E) ratio is 17.47, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of ADMA?
According to the latest financial report, Adma biologics, inc. (ADMA) reported an Operating Profit of 51.01M with an Operating Margin of 38.01% this period, representing a growth of 28.69% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ADMA's revenue growth?
In the latest financial report, Adma biologics, inc. (ADMA) announced revenue of 134.22M, with a Year-Over-Year growth rate of 12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ADMA have?
As of the end of the reporting period, Adma biologics, inc. (ADMA) had total debt of 73.73M, with a debt ratio of 0.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ADMA have?
At the end of the period, Adma biologics, inc. (ADMA) held Total Cash and Cash Equivalents of 61.39M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ADMA go with three margins increasing?
In the latest report, Adma biologics, inc. (ADMA) achieved the “three margins increasing” benchmark, with a gross margin of 56.3%%, operating margin of 38.01%%, and net margin of 27.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ADMA's profit trajectory and future growth potential.
What is the FCF of ADMA?
Adma biologics, inc. (ADMA)'s Free Cash Flow (FCF) for the period is -1.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 104.48% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.